Abstract: Crew egress pathways and crew egress pathway exits in aircraft, with the crew egress pathway exits comprising apparatuses, systems, and methods for reliable deployment and stowage of support straps within crew egress pathway exit hatches positioned, with crew egress pathway exit hatches configured to deploy within aircraft passenger compartments in aircraft.

Abstract: A medical product includes a bladder, a filtration device, and a sterile product concentrate. The bladder has a perimeter seal and defining a sterile chamber. The filtration device includes a stem and a filter membrane disposed in line with the stem. The stem extends through the perimeter seal and has an inlet end accessible from outside of the perimeter seal and an outlet end in fluid communication with the sterile chamber. The filter membrane can have a nominal pore size in a range of approximately 0.1 ?m to approximately 0.5 ?m, wherein the filter membrane is shaped as a hollow fiber with a wall and pores residing in the wall of the fiber. The sterile product concentrate is disposed in the sterile chamber and adapted to be reconstituted by the introduction of a pharmaceutical fluid into the chamber through the filtration device.

Abstract: The present disclosure provides novel compositions and methods for collectively transforming or genetically modifying a population of distinct germplasm of different germplasms or having different genotypes. The compositions of the present disclosure may include a population of distinct germplasm, such as embryo explants, and a heterologous polynucleotide molecule, a ribonucleoprotein, or a site-specific nuclease. The methods of the present disclosure may include one or more steps of explant preparation, explant rehydration, Rhizobiales bacterium inoculation and co-culture or particle bombardment, bud induction, extended bud induction, and/or regeneration or development of genetically modified plants or plant parts. The methods provided herein may include transforming at least one plant cell of the embryo explants with a heterologous polynucleotide.

Abstract: A recycling kiosk for recycling and financial remuneration for submission of an electronic device such as a mobile phone is disclosed herein. The recycling kiosk includes electrical connectors and an inspection area with an upper chamber, a lower chamber, a transparent plate and at least one camera in order to perform a visual analysis and an electrical analysis of the electronic device for determination of a value of the electronic device. The recycling kiosk also includes a processor and a display for user interaction.

Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

Abstract: The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides may be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labelling.

Abstract: A preparation device for preparing a sample for measurement of a target biomolecule in a probe of a bodily fluid is disclosed that includes a substrate with a capillary network configured to transport the probe of the bodily fluid along the substrate. The substrate may be provided with a fluorescent, reflective or self-luminescent marker adapted to bind with the target biomolecule to emit a reaction radiation when excited by an excitation source. The fluorescent, reflective or self-luminescent marker is adapted, when bound to the target biomolecule and excited by the excitation source, together with the target biomolecule to emit the reaction radiation at an intensity proportional to a quantity of the target biomolecule in the probe of the bodily fluid.

Abstract: The invention is in the field of cell biology and immunology. The invention provides methods for the production of a vaccine for cancer and infectious diseases. More in particular it provides a method for the improved production of mature dendritic cells. This improved production includes the use of a bacterial lysate produced by a new method.

Abstract: A system is disclosed that includes a computer. The computer includes a processor and a memory. The memory includes instructions such that the processor is programmed to: group a plurality of endpoints based on evaluation result data for each endpoint of the plurality of endpoints; determine a target system configuration for the group; and transmit the target system configuration to a software agent corresponding to each endpoint of the plurality of endpoints.

Abstract: Systems and methods for providing explainability for processing data through multiple layers are provided. An input layer is configured to receive an evidence data set comprising a plurality of evidence items, apply evidence processing models to the evidence data set to generate evidence understanding data, and generate input-layer explainability data, wherein the input-layer explainability data represents information about the processing of the evidence data set by the input layer. A presentation layer is configured to receive data (the evidence understanding data and/or data generated based on the evidence understanding data), apply one or more presentation generation models to the received data to generate presentation data, and generate presentation-layer explainability data for presentation to the user, wherein the presentation-layer explainability data represents information about the processing of the received data set by the presentation layer.

Abstract: The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.

Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.

Abstract: An antiviral face mask and a face mask insert that both manage airflow by separating an exhaled breath from an inhaled breath to avoid inhalation of potentially contaminated air and excess carbon dioxide and to filter an exhaled breath to diminish the amount of potentially contaminated carbon dioxide from an exhaled breath into the environment.

Abstract: An adjustable athletic bra that provides support laterally (side to side), vertically (up and down), and in and out to provide stability in multiple directions.

Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MEW class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

Abstract: The present invention relates to a method and apparatus for transferring heat energy from a waste-liquid, wherein the apparatus (100) comprises at least one heat exchange element (107) for transferring heat energy from waste liquid in a first container (101) to a first target fluid, at least one heat pump element (111) for transferring heat energy from waste-liquid transferred from the first container to the further container (102), at least one selectively operable exit-valve element (115) for selectively providing at least one fluid communication path for allowing waste-liquid to exit from the further container, and at least one controller element for selectively operating the heat pump element to transfer heat energy from waste-liquid in the further container to a further target fluid and/or for selectively operating the at least one selectively operable exit-valve element.

Abstract: Disclosed herein are novel PD-L1 binding molecules and methods of their use. The disclosed PD-L1 binding molecules include neutralizing anti-PD-L1 antibodies, bi-specific antibodies, and immunotoxins. The description provides for the use of the disclosed PD-L1 binding molecules in the treatment, prevention, inhibition, or reduction of a cancer or metastasis or as part of a treatment regimen including the use of other anti-cancer agents.

Abstract: A preparation device (1) for preparing a sample for measurement of a target biomolecule in a sample of a bodily fluid, such as anti-Mullerian hormone in blood, comprises a substrate (12) with a capillary network configured to transport the sample of the bodily fluid along the substrate, wherein the substrate (12) is provided with a fluorescent, reflective or self-luminescent marker adapted to bind with the target biomolecule, said fluorescent, reflective or self-luminescent marker being adapted, when bound to the target biomolecule and excited by an excitation source of a diagnostic apparatus, together with the target biomolecule to emit reaction radiation at an intensity proportional to a quantity of the target biomolecule in the probe of the bodily fluid. The preparation device may preferably comprise a near-field communication (NFC) chip (114) storing a unique identifier of the preparation device.